Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, antibody humanization patent manager PDL BioPharma (Nasdaq: PDLI ) has earned a respected four-star ranking.
With that in mind, let's take a closer look at PDL's business and see what CAPS investors are saying about the stock right now.
||Incline Village, Nev. (1986)
||CEO/Acting CFO John McLaughlin
Chief Accounting Officer Caroline Krumel
|Return on Capital (average, past 3 years)
||$210.8 million / $410.0 million
Sources: S&P Capital IQ; Motley Fool CAPS.
On CAPS, 95% of the 901 members who have rated PDL believe the stock will outperform the S&P 500 going forward.
Just last month, All-Star Fool austinhippie highlighted several of PDL's positives:
Looks about worth twice its current market price ... Good Margins ... cash flow is positive and relatively steady although not really growing ... a powerful dividend.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, PDL may not be your top choice.
We've found another small-cap play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.